September 2025 witnessed a whopping surge in North American import price of progesterone due to persistent supply chain disruptions, unstable raw material prices, and increasing global demand. Supply chain issues, based on past geopolitical tensions and trade barriers, have deterred sourcing key raw materials required for manufacturing progesterone. This has pushed manufacturers to shell out a premium for inputs, raising costs for consumers and healthcare providers. Volatility in material prices because of extreme weather patterns and shifts in regulation has also stretched production capacities equally. Furthermore, increasing global demand for hormonal therapy, fueled by increased knowledge of fertility health concerns, is building supply chain pressures. Inflation, combined with high freight costs and shortages of labor, also fuels the tensions. Experts warn that unless phenomenal gains in supply chain reliability and material pricing are realized, progesterone import prices will be sustained at elevated levels, fueled by an unstable economic climate and geopolitical tensions.
September **** witnessed a consistent and uniform increase in import costs of progesterone in the North American market. The facts indicate that the average import cost rose at a uniform rate with a synergy of factors that include supply chain breakdowns, volatile raw material costs, and rising global demand, which are most likely to continue their trend in the near future.
One of the highest contributing factors towards this cost increase has been the chronic supply chain issue that is currently plaguing the pharmacy sector, with values assembled at USD ******/MT CFR Los Angeles around *.***. This supply chain restrictor is geopolitical tensions and trade barrier lines that have inhibited freedom of goods movement, with key leverage over procurement of critical raw materials for progesterone manufacturing. As manufacturers contend with unstable supply chains, they compensate premium to acquire materials and transfer these costs to customers and healthcare...
Leave a Comment
Comments (0)